AMP945 Combined with FOLFIRINOX Enhances Treatment Effects in model of Pancreatic Cancer
- Written by PR Newswire Asia - News Pronto RSS
HIGHLIGHTS
- Amplia's highly selective FAK inhibitor AMP945, when used in combination with FOLFIRINOX, enhances survival in a preclinical model of pancreatic cancer
- FOLFIRINOX is the most widely used treatment for pancreatic cancer patients in the US, Canada and most European countries
- This new data supports clinical studies investigating the...
Read more: AMP945 Combined with FOLFIRINOX Enhances Treatment Effects in model of Pancreatic Cancer